VIATRIS INC. for VIATRIS INC
What was lobbied
6 issue areas, each in the filer's own words, with who lobbied on it and where.
Financial Institutions/Investments/Securities FIN
H.R. 4015 Corporate Governance Reform and Transparency Act of 2017 and oversight of proxy advisory firms
Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AKSHAI DATTA | — |
| DAVID MARIN | — |
Trade (domestic/foreign) TRD
Trade issues related to generic medicines
Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEBORAH AUTOR New | — |
| AKSHAI DATTA | — |
| KATHARINE HAYES | — |
| DAVID MARIN | — |
| MARCIE MCCLINTIC-COATES | — |
| NIMISH SHAH | — |
| PETER WALLACE New | 2008 Legislative Correspondent, Rep. Ric Keller |
Copyright/Patent/Trademark CPT
Issues related Inter Partes Review (IPR) process for biosimilars and generic drugs, Hatch-Waxman Integrity Act of 2018, Patent Settlements
Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AKSHAI DATTA | — |
| KATHARINE HAYES | — |
| DAVID MARIN | — |
| MARCIE MCCLINTIC-COATES | — |
Health Issues HCR
Drug pricing issues, access to generic medicines, Medicare Part D program and generic drugs Risk Evaluation and Mitigation Strategies (REMS), H.R. 2051 - FAST Generics Act of 2017, S.974, H.R. 2212 - CREATES Act of 2017 Biologics Price Competition and Innovation Act (BPCIA) transition provisions affecting Insulins, complex generics Medicare reimbursement for biosimilars, Pass through payments for biosimilars
Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEBORAH AUTOR New | — |
| AKSHAI DATTA | — |
| KATHARINE HAYES | — |
| DAVID MARIN | — |
| MARCIE MCCLINTIC-COATES | — |
| PETER WALLACE New | 2008 Legislative Correspondent, Rep. Ric Keller |
Budget/Appropriations BUD
Medicaid Rebate provision of the Bipartisan Budget Act of 2015
Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| AKSHAI DATTA | — |
| KATHARINE HAYES | — |
| DAVID MARIN | — |
| MARCIE MCCLINTIC-COATES | — |
| PETER WALLACE New | 2008 Legislative Correspondent, Rep. Ric Keller |
Tariff (miscellaneous tariff bills) TAR
Tariff issues related to generic medicines
Foreign entity interest: As the parent entities of Mylan Inc., Mylan NV and Mylan Holdings Limited have a general interest in the issues above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEBORAH AUTOR New | — |
| AKSHAI DATTA | — |
| DAVID MARIN | — |
| MARCIE MCCLINTIC-COATES | — |
| NIMISH SHAH | — |
Foreign entities
Foreign owners and affiliates the filer disclosed. Amounts are as declared on this filing.
| Entity | Country | Principal place of business | Ownership | Contribution declared |
|---|---|---|---|---|
| MYLAN NV | United Kingdom | United Kingdom | 100.0% | — |
| MYLAN HOLDINGS LIMITED | United Kingdom | United Kingdom | 100.0% | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.